SUGGESTED
TREATMENT PROTOCOLS
FOR CFS / FM
PATIENTS 1
| Heparin Time Line:
|__________|__________|__________|__________|__________|__________| Day 1 30 Days 60 Days 90 Days 120 Days 150 Days 180 Days Transfer Factor Time Line:
|
Heparin Protocol:
See instruction sheet of Dr. Couvaras.
(This sheet is not available online. Conact David Berg at 800-999-2568
or by email for more information about
this sheet).
For a 150# slender patient, use
4000units, sq, BID. If insurance will pay for LMWH (Lovenox), use
30 mg. in AM.
For a >150 # overweight
patient, use 5000 units, sq, BID. If insurance will pay for LMWH
(Lovenox), use 30 mg. in the morning and 15 mg. at night.
It is suggested that heparin be continued
for a time period after discontinuation of other therapies in order to
prevent any remaining pathogens from activating the coagulation mechanism
and starting the fibrin deposition cycle again.
Transfer Factor:
Transfer Factor (from colostrum) is available
from several sources. The source that we have patient data using this protocol
is Immunity Today, LLC (www.immunitytoday.com).
The dosage suggested by the company is 3 capsules per day. The cost is
$270 for a 1 month supply. TF is more effective if started after heparin
has been used for a period of time to allow some cleanup of fibrin deposition
from endothelial cell surfaces in the capillaries.
Antibiotics:
Antibiotics, such as Doxycyline, may be
used if there are known pathogens such as Mycoplasma or Chlamydia pneumonia.
Each clinician must make the decision to use or not to use antibiotics
based on their knowledge of their patient.
Bromelain:
Bromelain may be used as an activator
of fibrinolysis, especially in patients that have high Lp(a) or high PAI-1
values (which blocks fibrinolysis). A possible dosage is 500 to 1000 mg/day.
There is no data that states that bromelain helps in these patients, but
several journal articles suggest that bromelain does enhance fibrinolysis.
Since bromelain is a natural substance from pineapples, it is an alternative
to using tPA or Urokinase as fibrinolysis activators in patients.
1. This protocol should be used only under direction and supervision of the patient's physician. This suggested protocol has been developed by an Infectious Disease specialist and HEMEX Laboratories, Inc. In no way should a patient treat him/herself. HEMEX is in no way responsible for patient care. All drug precautions should be noted and followed. Questions can be addressed to dberg@hemex.com.